Key Pharmacy Recalls Hydroxo-B12 Injections Due to Sterility Concerns
Key Pharmacy and Compounding Center is recalling specific lots of Hydroxo-B12 injections because the firm cannot ensure the products are sterile.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II. Per the rubric, FDA Class II recalls involving significant risks such as sterility assurance failures in injectable drugs are classified as Severe (Score 4), particularly when structural or process defects in sterile products are involved.
Plain-English summary
Key Pharmacy and Compounding Center is recalling 8 vials of Hydroxo-B12 5mg/mL injection, including 10 mL and 30 mL multiple-dose glass vials. The recall involves three specific lots with expiration dates in April 2017. The products were distributed nationwide in the U.S.A., as well as in Australia and Canada.
The recall was initiated due to a lack of assurance of sterility. The firm is recalling these sterile compounded drugs because it cannot guarantee that the products remain sterile within their expiration dates.
Consumers and healthcare providers should stop using the affected vials immediately. Those who have received or purchased these specific lots should contact their healthcare provider or the recalling firm for further instructions on disposal or replacement.
The recalled product
- Product
- HYDROXO-B12 10ML PBF MDV 5MG/ML INJ, 5mg/mL, Rx only, 10 mL Glass/ Multiple Dose vial, Prepared by Key Compounding Pharmacy HYDROXO-B12 30ML PBF MDV 5MG/ML INJ, 5mg/mL, RX only, 30 mL Glass/ Multiple Dose vial.
- Manufacturer
- Key Pharmacy and Compounding Center
- Category
- Drug — Compounded Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # t01-20-2017@87
- Exp 4/23/2017
- t02-08-2017@99
- Exp 4/30/2017
- t02-21-2017@113
- Exp 4/30/2017.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 79 recalled by Key Pharmacy and Compounding Center under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 79 products in this recall →Related recalls
Same manufacturer · Key Pharmacy and Compounding Center
See all →- SevereKey Pharmacy Recalls Pyridoxal-5-Phosphate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls Sterile Compounded Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- HighKey Pharmacy Recalls Vitamin D3 Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls 5-MTHF Injections Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls Folic Acid Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15